PDCD1 and breast carcinoma: The main innovation of this study lies in the development of a novel pH-sensitive nano-vaccine that integrates a STING agonist and a breast cancer neoantigen (M32) into a polymeric system, specifically designed for synergistic use with anti-PD-1 therapy.